Page 16 - Aurobindo Pharma

Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales

Revenues from operations increased 21.5 percent to 5,269.7 crore during the quarter under review as compared to Rs 4336.1 crore in the year ago period

Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales

'We have delivered a robust revenue growth of 22%', said Aurobindo Pharma MD N Govindarajan

Aurobindo Pharma to acquire oncology products from US-based firm in $300 mn

Acrotech will be acquiring the product portfolio on a debt free and cash free basis, Aurobindo Pharma Ltd said in a regulatory filing

Aurobindo expects Sandoz buy to make it second-largest generics firm in US

The Hyderabad-based company is at fifth place in prescription sales, next to Indian counterpart Lupin, in the US

Aurobindo Pharma USA recalls 80 lots of blood pressure drug from US

To date, Aurobindo Pharma USA Inc has not received any reports of adverse events related to this recall, the company said

Aurobindo's injectable business grows 8% year-on-year to $50 mn in Q2

Analysts feel R&D costs are set to rise as a result of injectables and biosimilars focus

Aurobindo Pharma gets final approval from USFDA to market anaesthesia drug

The approved product is a generic equivalent of Organon's Norcuron Injection

Aurobindo Pharma gets USFDA nod to market potassium chloride pills in US

The potassium chloride tablets are for treating hypokalemia, a condition wherein there is a drop in the potassium-level in the blood

Aurobindo Pharma arm inks pact with Shandong Luoxin to form JV in China

The JV will also undertake contract manufacturing for non-nebuliser inhaler products

Aurobindo named in a lawsuit for selling adulterated irbesartan products

In October, Aurobindo Pharma announced a voluntary recall of 22 batches of irbesartan due to the detection of trace amounts of NDEA

Aurobindo Pharma hits 52-week high; up 56% in six months

The stock hit a 52-week high of Rs 830, up 3%, surging 55% in past six months, as compared to 3% rise in the S&P BSE Sensex.

Improving margins, reducing debt key challenges for Aurobindo Pharma

While revenue growth is expected to be strong, improving margins and reducing debt could be challenging

Aurobindo Pharma to launch oncology, respiratory products in US by 2021

The company is also planning to launch first set of biosimilars and vaccines in growth markets during this time, Aurobindo Pharma said in an investor presentation

Aurobindo expects drug filing opportunities in US to stay for another 5 yrs

The senior management of Aurobindo said they are looking at launching the Oncology products in the US market by the end of this year

Aurobindo inks pact to acquire Australian pharma firm for $12.5 mn

Based out of Melbourne, Advent Pharmaceuticals is engaged in developing and commercialising generic inhaled medicines for global markets.

Aurobindo Pharma slips 4% post Q2 nos; Credit Suisse, Citi remain bullish

The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs.

Aurobindo Pharma reports 21.7 per cent decline in profit, says expenses up

The company was able to improve its US formulations revenues by 6.1 per cent year-on-year at Rs 22.27 billion.

Aurobindo recalls 22 batches of hypertensive drug in US citing cancer risk

According to a notification by the American drug regulator on its website, these 22 batches of Irbesartan drug substance were supplied by the city-based Aurobindo to ScieGen Pharmaceuticals Inc

Aurobindo Pharma scouting for suitable acquisitions in domestic market

Recently, through the acquisition of Sandoz's dermatology and oral solids business, Aurobindo has now entered the branded OTC segment in the US

Aurobindo Pharma buys Sandoz's US business in $900 million deal

The deal gives the Hyderabad based company access to Sandoz's portfolio of oral solids and dermatology drugs and manufacturing footprint